Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human CD19 Protein, Fc tag, 2x500 µg  

Recombinant human CD19 Protein, Fc tag, 2x500 µg

Recombinant Human CD19 Protein (Pro20-Lys291), produced in human 293 cells (HEK293), Fc tag

Synonym
Recombinant Human protein, CD19, CD-19, B4, B-4, CVID3, CVID-3, MGC12802, B-lymphocyte antigen CD19, Cluster of Differentiation

More details

CD9-H5259-1K

Availability: within 7 days

2 400,00 €

Background
B-lymphocyte antigen CD19 also known as CD19 (Cluster of Differentiation 19), is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production.[1-2] CD19 has been shown to interact with: CD81,[3-5] CD82[5] , Complement receptor 2,[4-5] and VAV2.[6]

Source
Recombinant Human CD19 Protein, With C-Fc Tag (rhCD19-Fc) Pro20-Lys291 (Accession # AAH06338) was produced in human 293 cells (HEK293)

Molecular Characterization
rhCD19-Fc, fused with Fc fragment of human IgG1 at the C-terminus and has a calculated MW of 56.3 kDa expressed. The predicted N-terminus is Pro 20. Protein migrates as 56-66 kDa in reduced SDS-PAGE resulting from glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rhCD19-Fc by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
Immobilized Human PVRIG (Cat. No. PVG-H52H4) at 2 μg/mL (100 μL/well) can bind Human Nectin-2, Fc Tag (Cat. No. PV2-H5253) with a linear range of 0.2-3 ng/mL (QC tested). Immobilized Human Nectin-2, Fc Tag (Cat. No. PV2-H5253) at 10 μg/mL (100 μL/well) can bind Biotinylated Human TIGIT, Fc Tag, Avi Tag with a linear range of 0.156-2.5 μg/mL (Routinely tested).

References

(1) Pesando JM, et al., J. Exp. Med. 170 (6): 2159–64.
(2) van Zelm MC, et al., 2006, N. Engl. J. Med. 354 (18): 1901–12.
(3) Bradbury LE, et al., 1992, J. Immunol. 149 (9): 2841–50.
(4) Horváth G, et al., 1998, J. Biol. Chem. 273 (46): 30537–43.
(5) Imai T, et al., 1995, J. Immunol. 155 (3): 1229–39.
(6) Doody GM, et al., 2000, EMBO J. 19 (22): 6173–84.